VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi*, Anne-Marie Dingemans, Susanne Crowe, Solange Peters, Heinrich Roder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu-Fang Hsu Schmitz, Kyung-Jae Na, David Carbone, Rolf Stahel, Egbert Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)59-64
JournalLung Cancer
Issue number1
Publication statusPublished - Jan 2013


  • Biomarker
  • Chemotherapy
  • EGFR inhibitor
  • Lung cancer
  • Personalized medicine
  • Proteomics

Cite this